ComparisonInterventions

SGLT2 Inhibitors vs GLP-1 Receptor Agonists

Two outcome-proven classes with different strengths

SGLT2 InhibitorsGliflozins — heart-failure & kidney protection

GLP-1 Receptor AgonistsIncretin therapies — weight & atherosclerotic benefit

Last reviewed: July 2026
Version: 1.0
Review cadence: Annually

At a Glance

The 30-second view

Weight loss
SGLT2 Inhibitors
Modest
GLP-1 Receptor Agonists
Substantial
Heart failure
SGLT2 Inhibitors
Strong benefit
GLP-1 Receptor Agonists
Neutral
Kidney protection
SGLT2 Inhibitors
Strong
GLP-1 Receptor Agonists
Beneficial (esp. with albuminuria)
Atherosclerotic events
SGLT2 Inhibitors
Modest
GLP-1 Receptor Agonists
Proven reduction (e.g., semaglutide)
Administration
SGLT2 Inhibitors
Oral, daily
GLP-1 Receptor Agonists
Mostly injectable (some oral)

Dimension	SGLT2 Inhibitors	GLP-1 Receptor Agonists
Weight loss	Modest	Substantial
Heart failure	Strong benefit	Neutral
Kidney protection	Strong	Beneficial (esp. with albuminuria)
Atherosclerotic events	Modest	Proven reduction (e.g., semaglutide)
Administration	Oral, daily	Mostly injectable (some oral)

Overview

Both are modern, outcome-proven therapies used in type 2 diabetes and beyond, but their strengths differ. SGLT2 inhibitors excel at heart-failure and kidney protection; GLP-1 receptor agonists excel at weight loss and atherosclerotic cardiovascular benefit. They are often complementary, not mutually exclusive.

Quick summary

Choose based on the dominant problem: SGLT2 inhibitors for heart failure and chronic kidney disease; GLP-1 receptor agonists for substantial weight loss and atherosclerotic risk reduction. Both help glucose, and in higher-risk patients the two are increasingly combined. Neither is simply 'better' — they solve different problems.

When each is appropriate

Choose SGLT2 Inhibitors

When heart failure or chronic kidney disease is the priority (their strongest, best-proven benefit).

Choose GLP-1 Receptor Agonists

When substantial weight loss or atherosclerotic-event reduction is the priority.

Evidence comparison

Mechanism
SGLT2 Inhibitors
Urinary glucose excretion + cardiorenal effects
GLP-1 Receptor Agonists
Incretin (appetite, glucose, satiety)
Weight
SGLT2 Inhibitors
Modest loss
GLP-1 Receptor Agonists
Substantial loss
Heart failure
SGLT2 Inhibitors
Strong benefit (DAPA-HF, EMPEROR)
GLP-1 Receptor Agonists
Neutral
Kidney
SGLT2 Inhibitors
Strong (CREDENCE, DAPA-CKD)
GLP-1 Receptor Agonists
Beneficial (e.g., FLOW)
Atherosclerotic events
SGLT2 Inhibitors
Modest
GLP-1 Receptor Agonists
Proven reduction (SELECT, SUSTAIN-6)

Dimension	SGLT2 Inhibitors	GLP-1 Receptor Agonists
Mechanism	Urinary glucose excretion + cardiorenal effects	Incretin (appetite, glucose, satiety)
Weight	Modest loss	Substantial loss
Heart failure	Strong benefit (DAPA-HF, EMPEROR)	Neutral
Kidney	Strong (CREDENCE, DAPA-CKD)	Beneficial (e.g., FLOW)
Atherosclerotic events	Modest	Proven reduction (SELECT, SUSTAIN-6)

Safety comparison

Common issues
SGLT2 Inhibitors
Genital infections; rare euglycemic DKA
GLP-1 Receptor Agonists
GI (nausea); rare pancreatitis/gallbladder

Dimension	SGLT2 Inhibitors	GLP-1 Receptor Agonists
Common issues	Genital infections; rare euglycemic DKA	GI (nausea); rare pancreatitis/gallbladder

Strengths & limitations

SGLT2 Inhibitors

Best heart-failure and kidney protection

Oral, once-daily

Benefits without diabetes

Modest weight loss

Genital infections; DKA precautions

GLP-1 Receptor Agonists

Substantial weight loss

Proven atherosclerotic-event reduction

Broad metabolic benefit

Mostly injectable

GI side effects; higher cost; weight regain on stopping

Frequently asked questions

Which is better, SGLT2 inhibitors or GLP-1s?

Neither in the abstract — they excel at different things. SGLT2 inhibitors lead on heart failure and kidney protection; GLP-1s lead on weight loss and atherosclerotic risk. For high-risk patients, they're increasingly used together.

Can they be combined?

Yes — in higher-risk patients they're often combined, because their strongest benefits (cardiorenal vs weight/atherosclerotic) are complementary. That's a clinician decision.

Continue Exploring

Where to go next

References & sources

DAPA-HF / EMPEROR
CREDENCE / DAPA-CKD
SELECT / SUSTAIN-6
FLOW

Comparisons synthesize BioSignal's existing calibrated evidence — they introduce no new conclusions. Figures and verdicts trace to the linked Signal Records and Foundations.

Educational information — not medical advice

Comparisons orient a decision; they don't make it for you. Choices between medications, supplements, or programs belong with a qualified clinician. See our Medical Disclaimer.

Is this comparison clear, balanced, and useful? Your feedback shapes what we review next.

Give feedback